226-227 / 2437
Difficult to draw conclusions from small trials
OS no different in pooled analysis – possible
improvement in FIS and reduction of
neurological deaths
Pts likely to benefit: young age, good
neurological function and controlled
primary disease
Decision should be made in MDT
Brain metastases